These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 33651475)
21. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362 [TBL] [Abstract][Full Text] [Related]
22. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009 [TBL] [Abstract][Full Text] [Related]
23. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? Bergonzini C; Leonetti A; Tiseo M; Giovannetti E; Peters GJ Expert Opin Pharmacother; 2020 Aug; 21(11):1287-1298. PubMed ID: 32292093 [TBL] [Abstract][Full Text] [Related]
24. Treatment of Non-Small Cell Lung Cancer with Atypical EGFR Mutations. Wells L; Qin A Curr Treat Options Oncol; 2023 Dec; 24(12):1802-1814. PubMed ID: 38095779 [TBL] [Abstract][Full Text] [Related]
25. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M; Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527 [TBL] [Abstract][Full Text] [Related]
26. Dacomitinib, a new therapy for the treatment of non-small cell lung cancer. Brzezniak C; Carter CA; Giaccone G Expert Opin Pharmacother; 2013 Feb; 14(2):247-53. PubMed ID: 23294134 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study. Pu X; Zhou Y; Kong Y; Chen B; Yang A; Li J; Li K; Xu Y; Wu L BMC Cancer; 2023 Oct; 23(1):982. PubMed ID: 37840124 [TBL] [Abstract][Full Text] [Related]
28. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Keating GM Drugs; 2014 Feb; 74(2):207-21. PubMed ID: 24435321 [TBL] [Abstract][Full Text] [Related]
29. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application. Sun H; Wu YL Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844 [TBL] [Abstract][Full Text] [Related]
30. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations. Sehgal K; Rangachari D; VanderLaan PA; Kobayashi SS; Costa DB Oncologist; 2021 Apr; 26(4):281-287. PubMed ID: 32969527 [TBL] [Abstract][Full Text] [Related]
32. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803 [TBL] [Abstract][Full Text] [Related]
33. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib. Kudo K; Kawakado K; Kawajiri T; Nishi T; Makimoto G; Tamura T; Kuyama S; Tanimoto M Intern Med; 2020 Jul; 59(14):1739-1740. PubMed ID: 32296006 [TBL] [Abstract][Full Text] [Related]
34. Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations. Han C; Ding X; Li M; Luo N; Qi Y; Wang C J Cancer Res Clin Oncol; 2022 May; 148(5):1265-1268. PubMed ID: 35230510 [TBL] [Abstract][Full Text] [Related]
35. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation. Tanizaki J; Banno E; Togashi Y; Hayashi H; Sakai K; Takeda M; Kaneda H; Nishio K; Nakagawa K Lung Cancer; 2016 Nov; 101():11-15. PubMed ID: 27794398 [TBL] [Abstract][Full Text] [Related]
36. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050). Cheng Y; Mok TS; Zhou X; Lu S; Zhou Q; Zhou J; Du Y; Yu P; Liu X; Hu C; Lu Y; Zhang Y; Lee KH; Nakagawa K; Linke R; Wong CH; Tang Y; Zhu F; Wilner KD; Wu YL Lung Cancer; 2021 Apr; 154():176-185. PubMed ID: 33721611 [TBL] [Abstract][Full Text] [Related]
38. Dacomitinib: First Global Approval. Shirley M Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139 [TBL] [Abstract][Full Text] [Related]
39. Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases. Teng CK; Chen CL; Chen TH; Cheng WC; Tu CY Thorac Cancer; 2022 May; 13(9):1427-1430. PubMed ID: 35343086 [TBL] [Abstract][Full Text] [Related]
40. Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study. Jänne PA; Shaw AT; Camidge DR; Giaccone G; Shreeve SM; Tang Y; Goldberg Z; Martini JF; Xu H; James LP; Solomon BJ J Thorac Oncol; 2016 May; 11(5):737-747. PubMed ID: 26899759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]